People | December 04, 2025
Jubilant Pharmova appoints Daniel J. O Connor as CEO of Jubilant Therapeutics
O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors
O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
Angelini Ventures has already invested €125 million in 22 startups
The platform integrates with CT imaging and uses deep learning models to generate a 3D digital twin of lung anatomy
LYMPHIR addresses a clear clinical need in a disease with limited treatment options
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
Here's a new ray of hope for new hope for patients suffering from Meniere’s disease (MD) and sensorineural hearing loss
The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic
Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging
Subscribe To Our Newsletter & Stay Updated
